NEW YORK (GenomeWeb News) – The US Food and Drug Administration has told 23andMe that it must stop marketing its spit test and genome service to consumers because it has failed to address FDA's questions about the clinical and analytical validity of the product.

In a letter sent to company CEO Anne Wojcicki on Friday, the FDA said 23andMe must cease marketing the Saliva Collection Kit and Personal Genome Service to consumers immediately, and may not start marketing it again until it has received the agency's authorization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.